Recent Updates — EQ
Equillium, Inc. announced the dosing of its first subject in a Phase 1 single ascending dose clinical trial for EQ504, an investigational oral colon-targeted aryl hydrocarbon receptor modulator being developed for severe autoimmune and inflammatory disorders. This event triggered the Milestone Closing under a previously announced equity private placement agreement dated August 2025. The company issued 14,957,260 shares of common stock at $0.57 per share and 20,130,457 pre-funded warrants at $0.5669 per warrant, generating aggregate gross proceeds of approximately $20.0 million. This brings total equity private placement proceeds to approximately $50 million. The company expects these funds, combined with existing cash, to support operations into 2029. Equillium is a biotechnology innovator developing novel therapies for severe autoimmune and inflammatory disorders.
Equillium announced it has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification scheme for its Phase 1 clinical trial of EQ504. The company expects to begin dosing healthy participants by early November 2026. The randomized, double-blinded, placebo-controlled study will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily oral doses ranging from 0.1 to 3.0 mg. The trial includes single ascending dose, multiple ascending dose, and food effect cohorts, with gastrointestinal biopsies planned to assess target validation ahead of a Phase 2 proof-of-concept study. Equillium operates in the pharmaceutical industry, developing novel therapeutics for inflammatory conditions.
Equillium reported second quarter 2026 financial results with a net loss of $4.7 million, or $(0.04) per share, compared to a $5.7 million loss in the prior year period. Cash and cash equivalents totaled $57.2 million as of June 30, 2026, which management believes will fund operations into 2029. The company announced that its Phase 1 proof-of-mechanism study for EQ504 is expected to initiate in the fourth quarter of 2026, with topline data anticipated approximately six months later. Equillium operates as a clinical-stage biotechnology innovator developing therapies for severe autoimmune and inflammatory disorders.